Related references
Note: Only part of the references are listed.PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
Bob W. van Oosten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Manufacturer's Response to Case Reports of PML
Marianne T. Sweetser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PML in a Patient Treated with Fumaric Acid
Ummehan Ermis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action
R. Gold et al.
CLINICAL IMMUNOLOGY (2012)
Effects of dimethyl fumarate on neuroprotection and immunomodulation
Philipp Albrecht et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Fatal PML associated with efalizumab therapy Insights into integrin αLβ2 in JC virus control
N. Schwab et al.
NEUROLOGY (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Kamran Ghoreschi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis
D. G. MacManus et al.
JOURNAL OF NEUROLOGY (2011)
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
Gisa Ellrichmann et al.
PLOS ONE (2011)
Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions
Jack van Horssen et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
The Nrf2-ARE Pathway An Indicator and Modulator of Oxidative Stress in Neurodegeneration
Jeffrey A. Johnson et al.
MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS (2008)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Ludwig Kappos et al.
LANCET (2008)
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis
Eva Herrero-Herranz et al.
NEUROBIOLOGY OF DISEASE (2008)
A genomic screen for activators of the antioxidant response element
Yanxia Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research
Ralf Gold et al.
BRAIN (2006)
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration
S. Schilling et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study
S. Schimrigk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Detoxication enzyme inducers modify cytokine production in rat mixed glial cells
A Wierinckx et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders
Freek L. van Muiswinkel et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2005)
Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in downregulated Th1 lymphocyte responses
NHR Litjens et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Pharmacokinetics of oral fumarates in healthy subjects
NHR Litjens et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters
D Werdenberg et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2003)
Dimethylfumarate is a potent inducer of apoptosis in human T cells
F Treumer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells
R Loewe et al.
JOURNAL OF IMMUNOLOGY (2002)
Inhibition of dendritic cell differentiation by fumaric acid esters
KJ Zhu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells
TJ Stoof et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
Medical progress: Multiple sclerosis.
JH Noseworthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
